Brief: Innoviva Q2 Royalty Revenue USD 63.88 Million

Innoviva

06/08/2025 21:05

Overview

Innoviva Q2 royalty revenue at $67.3 mln, strong GSK portfolio performance

Net product sales rise 54% yr/yr to $35.5 mln, driven by U.S. sales

Net income at $63.7 mln, up from a $34.7 mln loss last year

Outlook

Innoviva working towards zoliflodacin FDA approval by Dec 15, 2025

Company sees multiple opportunities in current market environment

Result Drivers

ROYALTIES PERFORMANCE - Strong performance from GSK royalties portfolio contributed to $67.3 mln in revenue

U.S. SALES GROWTH - U.S. net product sales rose 54% yr/yr, driven by products like GIAPREZA and XACDURO

ZEVTERA LAUNCH - Launch of ZEVTERA in the U.S. marked a significant milestone in expanding product offerings

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Royalty Revenue
$63.88 mln
Q2 Net Income
$63.69 mln
Q2 Pretax Profit
$72.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Innoviva Inc is $40.00, about 53.9% above its August 5 closing price of $18.44

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nBw4KsSwza

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)